priors.science/reviews/sglt2-inhibitors

SGLT2 Inhibitors

The current evidence on 14 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

14claims tracked
96primary papers reviewed
6 Jul 2026latest evidence review
Weeklyre-scored against new papers
8 Established · 6 Likely · 0 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableSGLT2 inhibitors reduce CV death and HF hospitalisation in HFrEFHF RefEstablished96%7
StableSGLT2 inhibitors increase the risk of genital mycotic infectionsSafEstablished96%7
StableSGLT2 inhibitors slow kidney disease progression and reduce kidney failure riskCKDEstablished95%7
StableSGLT2 inhibitors reduce hospitalisation for heart failure in T2DCV T2DEstablished95%7
StableSGLT2 inhibitors reduce MACE in T2D with established cardiovascular diseaseCV T2DEstablished94%7
StableSGLT2 inhibitors reduce CV death and HF hospitalisation in HFpEFHF PefEstablished93%7
StableEmpagliflozin reduces cardiovascular death in T2D patients with established CVDCV T2DEstablished92%7
StableSGLT2 inhibitors are associated with euglycaemic diabetic ketoacidosisSafEstablished87%7
StableSGLT2 inhibitor kidney benefit extends to CKD patients without diabetesCKDLikely82%7
StableSGLT2 inhibitors reduce all-cause mortality in HFrEFHF RefLikely78%7
StableSGLT2 inhibitors do not significantly reduce CV mortality in HFpEFHF PefLikely78%7
StableSGLT2 inhibitors do not reduce MACE in T2D without established CVDCV T2DLikely76%7
StableCanagliflozin is associated with increased risk of lower limb amputationSafLikely72%7
StableSGLT2 inhibitor kidney benefit is greatest in patients with high albuminuriaCKDLikely68%7
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic